Literature DB >> 26374271

Compound heterozygous variants in the LARP7 gene as a cause of Alazami syndrome in a Caucasian female with significant failure to thrive, short stature, and developmental disability.

Tina T Ling1, Susanna Sorrentino1,2.   

Abstract

Alazami syndrome is an autosomal recessive disease characterized by primordial dwarfism, distinct dysmorphic features, and severe intellectual disability. Since it was first identified in a large consanguineous Arabic family in 2012, additional cases have not been published in the literature. We present a 2-year-old Northern European/Caucasian female with short stature, failure to thrive, and developmental delay. Whole exome sequencing (WES) identified two novel pathogenic variants in LARP7 (c.213_214dup and c.651_655del), indicating a diagnosis of Alazami syndrome. The case report describes a novel genotypic and phenotypic presentation of Alazami syndrome, contributing to the current knowledge of the condition as well as the expansion of differential diagnoses for growth restriction and intellectual disability.
© 2015 Wiley Periodicals, Inc.

Entities:  

Keywords:  Alazami syndrome; LARP7; intellectual disability; primordial dwarfism; short stature

Mesh:

Substances:

Year:  2015        PMID: 26374271     DOI: 10.1002/ajmg.a.37396

Source DB:  PubMed          Journal:  Am J Med Genet A        ISSN: 1552-4825            Impact factor:   2.802


  9 in total

1.  Structural basis for recognition of human 7SK long noncoding RNA by the La-related protein Larp7.

Authors:  Catherine D Eichhorn; Yuan Yang; Lucas Repeta; Juli Feigon
Journal:  Proc Natl Acad Sci U S A       Date:  2018-06-26       Impact factor: 11.205

2.  Stabilize and connect: the role of LARP7 in nuclear non-coding RNA metabolism.

Authors:  Daniele Hasler; Gunter Meister; Utz Fischer
Journal:  RNA Biol       Date:  2020-06-03       Impact factor: 4.652

3.  Updating the neurodevelopmental profile of Alazami syndrome: Illustrating the role of developmental assessment in rare genetic disorders.

Authors:  Monica H Wojcik; Kate Linnea; Joan M Stoler; Leonard Rappaport
Journal:  Am J Med Genet A       Date:  2019-05-10       Impact factor: 2.802

4.  hLARP7 C-terminal domain contains an xRRM that binds the 3' hairpin of 7SK RNA.

Authors:  Catherine D Eichhorn; Rahul Chug; Juli Feigon
Journal:  Nucleic Acids Res       Date:  2016-09-26       Impact factor: 16.971

5.  Broadening the phenotypic spectrum of pathogenic LARP7 variants: two cases with intellectual disability, variable growth retardation and distinct facial features.

Authors:  Iris H I M Hollink; Majid Alfadhel; Anwar S Al-Wakeel; Farough Ababneh; Rolph Pfundt; Stella A de Man; Rami Abou Jamra; Arndt Rolfs; Aida M Bertoli-Avella; Ingrid M B H van de Laar
Journal:  J Hum Genet       Date:  2015-11-26       Impact factor: 3.172

Review 6.  The La and related RNA-binding proteins (LARPs): structures, functions, and evolving perspectives.

Authors:  Richard J Maraia; Sandy Mattijssen; Isabel Cruz-Gallardo; Maria R Conte
Journal:  Wiley Interdiscip Rev RNA       Date:  2017-08-07       Impact factor: 9.957

7.  de novo MEPCE nonsense variant associated with a neurodevelopmental disorder causes disintegration of 7SK snRNP and enhanced RNA polymerase II activation.

Authors:  Pauline E Schneeberger; Tatjana Bierhals; Axel Neu; Maja Hempel; Kerstin Kutsche
Journal:  Sci Rep       Date:  2019-08-29       Impact factor: 4.379

8.  Novel compound heterozygous variants in the LARP7 gene in a patient with Alazami syndrome.

Authors:  Sumito Dateki; Tasuku Kitajima; Toshiharu Kihara; Satoshi Watanabe; Koh-Ichiro Yoshiura; Hiroyuki Moriuchi
Journal:  Hum Genome Var       Date:  2018-03-29

9.  Compound Phenotype Due to Recessive Variants in LARP7 and OTOG Genes Disclosed by an Integrated Approach of SNP-Array and Whole Exome Sequencing.

Authors:  Pietro Palumbo; Orazio Palumbo; Maria Pia Leone; Ester di Muro; Stefano Castellana; Luigi Bisceglia; Tommaso Mazza; Massimo Carella; Marco Castori
Journal:  Genes (Basel)       Date:  2020-03-31       Impact factor: 4.096

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.